A healthcare professional discusses with a patient clinical trial summary results.

Strategic Solutions: Building Sustainable Implementation

The new ICH E6(R3) compliance requirements, combined with the updated Declaration of Helsinki (2024 revision) ethical standards, provide compelling backing for plain language initiatives. Use this regulatory foundation to build your business case with senior management. The question has shifted from "Why should we do this?" to "How do we implement this requirement effectively?"

Neither sponsor websites nor regional registries fully solve the access problem: company sites are fragmented, and registries remain limited to specific geographies. The only global, sponsor-agnostic solution available today is TrialSummaries.com, which addresses key implementation barriers by:

  • Global accessibility: Summaries reach 165 countries with 17,000+ downloads, demonstrating genuine patient demand across diverse populations and regulatory environments
  • Reduced legal concerns: Sponsor-neutral hosting minimizes promotional risk perceptions
  • Simplified processes: Single point of submission rather than managing multiple company websites
  • Site engagement: Provides a consistent link sites can share across all studies

Rather than implementing study-by-study, build systematic processes that work across your entire portfolio. This includes:

  • Standardized consent language for new studies
  • Template approaches for summary writing and review
  • Clear role definitions between clinical, regulatory, and disclosure teams
  • Site agreement provisions that build transparency expectations into contracts

Create clear communication bridges between your GCP compliance teams and disclosure teams. The new regulatory compliance requirements for treatment assignment disclosure and results sharing provide natural touchpoints for coordination. Many organizations are discovering efficiency gains when these traditionally separate functions work together.

Most successful organizations follow a phased approach: Start with two to three pilot studies to test your processes and identify workflow gaps. Use these learnings to develop standardized procedures, then scale across your portfolio. This approach typically takes six to 12 months from pilot to full implementation, but ensures sustainable, compliant processes rather than ad-hoc solutions.

Sponsor accessing TrialSummaries.com on a laptop device.

Today, more than 23 sponsors are already participating in TrialSummaries.com, leveraging shared infrastructure to scale efficiently. These companies aren’t necessarily the largest or most resourced — they are the ones that have systematically addressed challenges and taken advantage of proven platforms to reduce duplication, manage risk, and reach patients globally.

Your organization likely has most of the pieces needed for success. The key is connecting them into sustainable, patient-centered processes that fit your operational realities.


Ready to explore how your organization can implement scalable plain language summary processes? We'd welcome the opportunity to share specific insights from successful implementations across 23+ sponsor organizations and how their approaches might address your operational challenges. Let’s continue the conversation about building transparency solutions that not only work for your organization but also honor the time and trust of the patients who participated in your research.

著者について

Headshot of Francine Lane, Senior Director of Product Management for TrialScopes Disclose at Citeline.

Francine Lane

VP of Global Transparency, Citeline

Francine Lane is Senior Director of Product at Citeline and former chair of the Drug Information Association (DIA) Clinical Trial Disclosure Community. Francine is responsible for helping TrialScope Disclose and TrialSummaries.com customers meet and exceed current disclosure expectations globally, giving them the tools they need to satisfy the requirements in this evolving industry. Francine also dedicates her time building relationships with external stakeholders — including sponsors, investigators, regulators, and transparency and patient advocates — to help align the goals and expectations of these groups, as well as help identify more consistent ways sponsors can meet transparency expectation and requirements.

関連コンテンツ

The United States Capitol building at sunset.
OCT 17, 2025
Article
薬事規制関連支援サービス

ClinicalTrials.gov and the US Government Shutdown: What Sponsors Need to Know

The US government shutdown is affecting ClinicalTrials.gov operations. Sponsors are unsure about the status of their registrations. Studies required under US law or policy are being processed. For other studies, sponsors report delays in public posting.

''
APR 16, 2025
Article
薬事規制関連支援サービス

GCP in 2025: A Transparency Revolution

See what the GCP Guidance updates mean for disclosure, plain language, and participant trust in terms of clinical research transparency.

Beyond Compliance: A Strategic Approach to Clinical Trial Disclosure Maturity
FEB 27, 2025
Webinar
薬事規制関連支援サービス

Beyond Compliance: 臨床試験情報開示の成熟度に対する戦略的アプローチ

This session introduces a comprehensive maturity model framework for clinical trial disclosure, helping organizations assess and enhance their capabilities across eight critical domains.